MEDI8968 600 mg IV, 300 mg SC
CD-RI-MEDI8968-1103
Phase 2 mab completed
Quick answer
MEDI8968 600 mg IV, 300 mg SC for Chronic Obstructive Pulmonary Disease is a Phase 2 program (mab) at MedImmune with 1 ClinicalTrials.gov record(s).
Program details
- Company
- MedImmune
- Indication
- Chronic Obstructive Pulmonary Disease
- Phase
- Phase 2
- Modality
- mab
- Status
- completed